Vascular Biogenics Ltd

Vascular Biogenics — Merger or Acquisition (February 2023)

25 slides from Vascular Biogenics's merger presentation, Feb 23, 2023

  1. Slide 1: VBL Therapeutics Proposed Merger With Notable Labs

    Slide 1: VBL Therapeutics Proposed Merger With Notable Labs

    VBL Therapeutics Proposed Merger With Notable Labs February 23, 2023

  2. Slide 2: Cautionary Note Regarding Forward Looking Statements

    Slide 2: Cautionary Note Regarding Forward Looking Statements

    Cautionary Note Regarding Forward Looking Statements ‘This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Secures Ligation Reform Act of 1995, including but not mite to, express or mplied statements regarding the structure, timing

  3. Slide 3: Additional Information About the Proposed Merger

    Slide 3: Additional Information About the Proposed Merger

    Additional Information About the Proposed Merger Additional Information About the Proposed Merger and Where to Find It This communication relates to the proposed merger transaction involving Vascular Biogenics, Ltd. (doing business as VBL Therapeutics) and Notable Labs and may be deemed to be solici

  4. Slide 4: Proposed Notable Labs & VBL Therapeutics Merger

    Slide 4: Proposed Notable Labs & VBL Therapeutics Merger

    Proposed Notable Labs & VBL Therapeutics Merger ° BS Notable Follows VBL Therapeutics extensive review of strategic alternatives All-stock transaction: VBL Therapeutics to acquire all outstanding shares of Notable Labs in exchange for newly issued ordinary shares of VBL Therapeutics Notable Labs sto

  5. Slide 5: Defining predictive precision medicine

    Slide 5: Defining predictive precision medicine

    * Defining predictive precision medicine, we aim to dramatically improve patient outcomes and the success, speed and RO! on drug development. Notable

  6. Slide 6: Traditional Precision Medicines Are Limited

    Slide 6: Traditional Precision Medicines Are Limited

    Traditional Precision Medicines Are Limited Patients Urgently Need Approaches Going Beyond Genetic Mutations Less than 15% of cancer patients? carry a known actionable genetic marker, and thus can benefit from traditional precision medicines In many clinical settings, trad itional precision medicine

  7. Slide 7: Predicting Clinical Response With a Goal of Improving Patient Outcomes

    Slide 7: Predicting Clinical Response With a Goal of Improving Patient Outcomes

    Predicting Clinical Response With a Goal of Improving Patient Outcomes and De-Risking Drug Development Business Model Biology & Technology * Reliably identifies patients most likely to respond to a treatment (does not need genetic markers) * Generates multidimensional measures of biological response

  8. Slide 8: Predictive Precision Medicine Platform (PPMP)

    Slide 8: Predictive Precision Medicine Platform (PPMP)

    Predictive Precision Medicine Platform (PPMP) Designed to Predict Patient Response Within Clinically Actionable Timeframe 3 3 Patient PPMP. Predicted Sample Platform Responders fi Patient Response ee Add Drug ‘or Drug Combination Predictive Precision translates into Response Rate

  9. Slide 9: PPMP Merges Biology and Technology

    Slide 9: PPMP Merges Biology and Technology

    PPMP Merges Biology and Technology Designed to Overcome the Limitations of Traditional Precision Medicines and Al- Driven Drug Design Replaces one-dimensional targeting with ___ Puts biology back multi-dimensional response measuring into computational models BS Notable 9

  10. Slide 10: Superior Differentiation of Notable's Business Model

    Slide 10: Superior Differentiation of Notable's Business Model

    Superior Differentiation of Notable’s Business Model Target the most compelling assets available using PPMP Fast-track remaining development selectively in responding patients with smaller and less costly trials Deliver a superior competitive profile and new patent life atform + product) as Notable

  11. Slide 11: We Aspire to Dramatically Improve Outcomes for Patients — Predictably

    Slide 11: We Aspire to Dramatically Improve Outcomes for Patients — Predictably

    We Aspire to Dramatically Improve Outcomes for Patients — Predictably Medical Practice Today Notable Labs Vision Chose between treatments with less than 30% response rate based on complex literature/guidelines Simply test first and selectively treat predicted responders 100 100 80 80 | 60 60 40 40 o

  12. Slide 12: Notable's Target Impact

    Slide 12: Notable's Target Impact

    Notable’s Target Impact * Higher Market Penetration * Benefits for Payers * Optimized Drug Combinations Predict & Select Responding + New Patent Life Patients De-Risked * Smaller Wie Drug Development [launder 9g P + Lower Cost ha Notable

  13. Slide 13: Predictive Precision Medicines Pipeline

    Slide 13: Predictive Precision Medicines Pipeline

    Predictive Precision Medicines Pipeline Lead indications target high unmet medical needs ~ as volaserti AME .|— o> = al AM — 80 CicloMed B

  14. Slide 14: Notable's Predictive Precision Medicine Platform Merges Biology & Technology

    Slide 14: Notable's Predictive Precision Medicine Platform Merges Biology & Technology

    Notable’s Predictive Precision Medicine Platform Merges Biology & Technology Cytokines/ Growth Factors Multiple Readouts at the Single Cell Level Media Components Stromal ‘Components @ @ Dying (Apoptosis) @ @ roteraive turing (Differentiating) Cancer 6 © MICROENVIRONMENT PARAMETERS Assay Model PROTO

  15. Slide 15: Differentiation: Notable Has Created A Massive Data Repository

    Slide 15: Differentiation: Notable Has Created A Massive Data Repository

    Differentiation: Notable Has Created A Massive Data Repository tior i 190 billion Notable receives up to 10% ofa ines of data given day’s AML patients in the U.S. Cumulative Number of Samples Other Ovarian, APL Lymphoma’ acl =CMML mBALL MALL =MPN =MML mpAML Healthy MM mcLL MDS mAML 45

  16. Slide 16: Notable's Clinical Validation Studies

    Slide 16: Notable's Clinical Validation Studies

    Notable’s Clinical Validation Studies Stanford University 54 Unique HR-MDS Patients 10 Adult AML Patients 20 De Novo Pediatric AML Patients Screened Against 74 ‘Compounds and 36 Combinatior 21 Patients Treated With Ser ‘Compounds | 11 Predicted Respond MDAnderson -Ganeer Network Standard-Of-Care Tre

  17. Slide 17: PPMP Has Demonstrated 83-100% Predictive Precision

    Slide 17: PPMP Has Demonstrated 83-100% Predictive Precision

    PPMP Has Demonstrated 83-100% Predictive Precision In three clinical validation studies with world-class medical centers Stanford University Mp Anderson Cancer Center Texas Children’s Hospital Washington University To be presented at AACR in April 2023 Notable Score C teen? > - Glnieat lineal linia

  18. Slide 18: Predictive Precision Translates Into Clinical Response Rate

    Slide 18: Predictive Precision Translates Into Clinical Response Rate

    Predictive Precision Translates Into Clinical Response Rate Predictive Precision is defined as how many PPMP-predicted responders achieved a clinical response in the real world Predictive 9 9 y Prolite 100% 83% 100% To be presented at AACR in April Mean 0.92 0.80 1.00 2023 [95% Cl] [0.69-1.00] [0.50

  19. Slide 19: Volasertib was Identified Using a PPMP-Driven Search for High-Value Assets

    Slide 19: Volasertib was Identified Using a PPMP-Driven Search for High-Value Assets

    Volasertib was Identified Using a PPMP-Driven Search for High-Value Assets Demonstrated Outstanding Clinical Activity & Y Platform Y Tolerability Performance ~ Demonstrated clinical activity signal in » Quickly move to MTA to procure - Compelling clinical activity in a subset defined population (10-

  20. Slide 20: Volasertib Response Rate in Notable's Avatar Trial

    Slide 20: Volasertib Response Rate in Notable's Avatar Trial

    Volasertib Response Rate in Notable’s Avatar Trial Matched Boehringer Ingelheim’s Phase 2/3 Response Rate Results: * 30% (20/65) of patients demonstrated ex vivo response z * Avatar response rate = Phase 2 & 3 clinical response rate + Patient population going forward = Predicted responders in Avatar

  21. Slide 21: Development Strategy Designed to Reduce Patient Numbers, Time and Cost

    Slide 21: Development Strategy Designed to Reduce Patient Numbers, Time and Cost

    Development Strategy Designed to Reduce Patient Numbers, Time and Cost 75% fewer patients vs. traditional trials FDA-Approved Therapeutic FDA-Approved Diagnostic o 6 2 18 24 30 36 “cutoff decision will be based on scientific and commercial considerations Protected sales for 20)yrs. Drug development

  22. Slide 22: Volasertib and Fosciclopirox Development Plans

    Slide 22: Volasertib and Fosciclopirox Development Plans

    Volasertib and Fosciclopirox Development Plans: Notable anticipates delivering multiple near-term value-inflection milestones Date Drug + PPMP Desc: 2Q 2023 PPMP. Fourth Clinical Validation Study at AACR 3Q 2023 Volasertib Phase 2A Trial Initiation in Adult AML. 4Q 2023 Fosciclopirox let Ela hace in

  23. Slide 23: Experienced Management Team

    Slide 23: Experienced Management Team

    Experienced Management Team Notable’s management integrate expertise and innovation across therapeutics, diagnostics and engineering Key Investors builders Thomas Bock Joseph Wagner Matt De Silva MD, MBA. PhD: B poe Chit Sci comes — a BS poem een Gow xe pifacell YDB mee = ‘cExion AONCOCYTE: hencnore

  24. Slide 24: Our Vision: Transform Patient Outcomes Through Predictive Precision Medicines

    Slide 24: Our Vision: Transform Patient Outcomes Through Predictive Precision Medicines

    Our Vision: Transform Patient Outcomes Through Predictive Precision Medicines Patient by Patient, Cancer by Cancer Biology + Fast-Paced Technology Value Inflection

  25. Slide 25: Thank You

    Slide 25: Thank You

Source: SEC EDGAR · 425 filed Feb 23, 2023

More decks from Vascular Biogenics Ltd